Novartis Corporation Must Wait Longer for FDA Lung Drug Decision

(Reuters) - Swiss drugmaker Novartis (NOVN.VX) will have to wait an extra three months to find out if U.S. authorities will back its new lung medicine, which would open the way for a potential new blockbuster drug.